Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s traded shares stood at 0.37 million during the last session, with the company’s beta value hitting 2.61. At the close of trading, the stock’s price was $9.30, to imply a decrease of -5.01% or -$0.49 in intraday trading. The KZIA share’s 52-week high remains $79.00, putting it -749.46% down since that peak but still an impressive 69.25% since price per share fell to its 52-week low of $2.86.

Analysts have given a consensus recommendation of Buy for Kazia Therapeutics Limited ADR (KZIA), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give KZIA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.

Kazia Therapeutics Limited ADR (NASDAQ:KZIA) trade information

After registering a -5.01% downside in the last session, Kazia Therapeutics Limited ADR (KZIA) has traded red over the past five days. The 5-day price performance for the stock is 64.60%, and 155.73% over 30 days. With these gigs, the year-to-date price performance is 5.08%.

KZIA Dividends

Kazia Therapeutics Limited ADR has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

The next major institution holding the largest number of shares is SUSQUEHANNA INTERNATIONAL GROUP, LLP with 41478.0 shares, or about 0.173% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $9457.0.

Going by data provided on Apr 30, 2025 , Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund holds roughly 196.0 shares. This is just over 0.02% of the total shares, with a market valuation of $1822.0